Insulin Receptor Substrate 1 (Irs 1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Insulin receptor substrate 1 ([IRS-1) is a 131 kDa signaling adaptor protein that serves as the primary intracellular mediator of insulin and insulin-like growth factor 1 (IGF-1) receptor signaling. Encoded by the IRS1 gene on chromosome 2q36.3, [IRS-1[/entities/irs-1 acts as a docking platform that is phosphorylated on tyrosine residues by activated insulin/IGF-1 receptors, subsequently recruiting downstream effectors including [PI3K]/[Akt[/proteins/akt-protein and Ras/MAPK pathways that regulate glucose metabolism, cell survival, synaptic plasticity, and [autophagy[/entities/autophagy (White, 2003).
[IRS-1[/entities/irs-1 dysregulation has emerged as a critical molecular link between brain insulin resistance and [Alzheimer's disease[/diseases/alzheimers (AD), earning AD the designation "type 3 diabetes." In AD brain tissue, [IRS-1[/entities/irs-1 exhibits pathological serine hyperphosphorylation (which inhibits its function) while tyrosine phosphorylation (which activates signaling) is reduced, resulting in impaired insulin/IGF-1 signaling that promotes tau] hyperphosphorylation, [amyloid-beta[/entities/amyloid-beta accumulation, synaptic dysfunction, and neuronal death (Talbot et al., 2012).
¶ Structure and Function
¶ Protein Domains
[IRS-1[/entities/irs-1 contains several functional domains:
- Pleckstrin Homology (PH) domain: Mediates membrane localization via phosphoinositide binding, bringing [IRS-1[/entities/irs-1 into proximity with the insulin receptor
- Phosphotyrosine Binding (PTB) domain: Binds the NPXY motif of the activated insulin receptor
- Multiple tyrosine phosphorylation sites: ~20 tyrosine residues serve as docking sites for SH2 domain-containing proteins when phosphorylated (PI3K regulatory subunits p85α/β, Grb2, SHP2, Nck)
- Multiple serine/threonine phosphorylation sites: >50 serine/threonine residues that, when phosphorylated, generally inhibit [IRS-1[/entities/irs-1 function (negative feedback or pathological inhibition)
When insulin or IGF-1 binds its receptor, the receptor autophosphorylates and then tyrosine-phosphorylates [IRS-1[/entities/irs1, initiating two major pathways:
- Tyrosine-phosphorylated IRS-1 recruits PI3K regulatory subunits (p85)
- PI3K generates PIP3, recruiting Akt (protein kinase B) to the membrane
- Akt is activated by PDK1 and [mTORC2]
- Akt phosphorylates and inhibits [GSK-3β[/entities/gsk3-beta, reducing tau phosphorylation and glycogen synthase kinase activity
- Akt activates [mTORC1], promoting protein synthesis and inhibiting [autophagy[/entities/autophagy
- Akt promotes neuronal survival by phosphorylating and inactivating pro-apoptotic Bad and FoxO transcription factors
- Tyrosine-phosphorylated IRS-1 recruits Grb2/SOS
- SOS activates Ras → Raf → MEK → ERK cascade
- ERK promotes gene expression related to cell growth, synaptic plasticity, and [long-term potentiation[/entities/long-term-potentiation
In the brain, insulin/IGF-1 signaling via IRS-1 is essential for:
- Synaptic plasticity and memory: Insulin signaling facilitates [LTP[/entities/long-term-potentiation in the [hippocampus[/brain-regions/hippocampus and promotes AMPA receptor trafficking to synapses
- [Tau[/entities/tau-protein phosphorylation regulation: Akt-mediated [GSK-3β[/entities/gsk3-beta inhibition is the primary mechanism preventing pathological tau hyperphosphorylation
- Neuronal survival: Anti-apoptotic signaling through Akt/FoxO and Bcl-2 family regulation
- Glucose metabolism: Neuronal glucose uptake and utilization, particularly in the [hippocampus[/brain-regions/hippocampus and [cortex[/brain-regions/cortex
- [autophagy[/entities/autophagy regulation: mTORC1-dependent regulation of macroautophagy and [TFEB[/entities/tfeb nuclear translocation
Brain insulin resistance in AD is characterized by impaired IRS-1 signaling:
- Serine hyperphosphorylation: In AD brain, IRS-1 is pathologically phosphorylated on inhibitory serine residues (Ser312, Ser616, Ser636/639) by stress kinases including JNK, IKKβ, PKR, and [mTOR[/mechanisms/mtor-neurodegeneration. This serine phosphorylation blocks tyrosine phosphorylation and promotes IRS-1 degradation (Bomfim et al., 2012)
- Reduced tyrosine phosphorylation: Activating tyrosine phosphorylation of IRS-1 is decreased by ~50% in AD [hippocampus[/brain-regions/hippocampus compared to controls
- Reduced insulin receptor expression: Insulin receptor density and insulin receptor tyrosine kinase activity are decreased in AD brain
- Elevated IRS-1 pSer in CSF/plasma: Phospho-Ser312 and phospho-Ser616 IRS-1 are elevated in AD patient exosomes and CSF, serving as potential [biomarkers]
IRS-1 dysfunction in AD produces multiple pathological effects:
-
[GSK-3β[/entities/gsk3-beta activation: Loss of Akt-mediated inhibition of [GSK-3β[/entities/gsk3-beta leads to:
- Tau hyperphosphorylation at multiple epitopes (Thr181, Ser202/Thr205, Thr231)
- Glycogen metabolism disruption
- Increased [amyloid-beta[/entities/amyloid-beta production via [APP[/genes/app processing modulation
-
[mTOR[/mechanisms/mtor-neurodegeneration dysregulation: Paradoxically, while upstream insulin signaling is impaired, [mTOR[/mechanisms/mtor-neurodegeneration may be chronically activated in AD, causing:
- Impaired [autophagy[/entities/autophagy, reducing clearance of [Aβ[/entities/amyloid-beta and tau aggregates
- Translational dysregulation
- [TFEB[/entities/tfeb nuclear exclusion, impairing lysosomal biogenesis
-
Synaptic dysfunction: Impaired insulin signaling reduces:
- AMPA receptor surface expression
- [BDNF[/entities/bdnf signaling
- Dendritic spine density
- [Long-term potentiation[/entities/long-term-potentiation in hippocampal circuits
-
neuroinflammation feedback: TNFα and IL-1β produced by activated [Microglia[/neuroinflammation,) reinforcing insulin resistance and neurodegeneration.
[Amyloid-Beta[/entities/amyloid-beta oligomers directly induce IRS-1 dysfunction through:
- Binding to and removing insulin receptors from the neuronal surface
- Activating TNFα/JNK signaling cascades that serine-phosphorylate IRS-1
- Competing with insulin for receptor binding
- Activating PKR (double-stranded RNA-dependent protein kinase), which phosphorylates eIF2α and IRS-1
Targeting brain insulin resistance via IRS-1 pathways is an active area of AD therapeutics:
- Intranasal insulin: Bypasses the [Blood-Brain Barrier[/entities/blood-brain-barrier; clinical trials show improved cognition and reduced brain hypometabolism in MCI/mild AD. Phase II/III trials have yielded mixed but encouraging results (Craft et al., 2020)
- [GLP-1 receptor agonists[/treatments/glp1-receptor-agonists: Liraglutide, semaglutide, and exenatide enhance brain insulin signaling and reduce IRS-1 serine phosphorylation. The ELAD trial of liraglutide in AD showed reduced cerebral glucose decline. Semaglutide is in Phase III AD trials.
- Metformin: AMPK activator that improves insulin sensitivity; epidemiological studies show reduced AD risk in diabetic patients taking metformin
- PPARγ agonists: Rosiglitazone and pioglitazone improve insulin sensitivity; pioglitazone showed promise in AD prevention trials (TOMORROW trial)
- JNK inhibitors: Block stress-kinase-mediated IRS-1 serine phosphorylation
- GSK-3 inhibitors: [Tideglusib[/treatments/tideglusib, lithium, and other [GSK-3β[/entities/gsk3-beta inhibitors address downstream consequences of IRS-1 dysfunction
- [mTOR[/mechanisms/mtor-neurodegeneration modulators: Rapamycin analogs restore autophagy in AD models
While IRS-1 is the predominant insulin signaling mediator, IRS-2 also plays important brain roles:
| Feature |
IRS-1 |
IRS-2 |
| Primary receptor |
Insulin receptor, IGF-1R |
Insulin receptor, IGF-1R |
| Brain expression |
Widespread, enriched in [hippocampus[/brain-regions/hippocampus, [cortex[/brain-regions/cortex |
Widespread, enriched in hypothalamus |
| AD involvement |
Serine hyperphosphorylation → signaling blockade |
Expression reduced in AD |
| Mouse knockout |
Insulin resistance, growth retardation |
Diabetes, reduced brain size |
| Amyloid effect |
IRS-1 dysfunction increases [Aβ[/entities/amyloid-beta |
IRS-2 deletion reduces [Aβ[/entities/amyloid-beta (paradoxically) |
The study of Insulin Receptor Substrate 1 (Irs 1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.